NCT01498679 - Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry. | Biotech Hunter

Enrollment

311

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions

Asthma

Interventions

DRUG

GW685698/GW642444 (fluticasone furoate/vilanterol trifenatate)

ICS/LABA combination (100/25mcg) administered once daily in the evening via a Novel Dry Powder Inhaler (NDPI)

DRUG

Placebo

Placebo administered once daily in the evening via a NDPI

Trial Locations (28)

1101

GSK Investigational Site, Quezon City

3019

GSK Investigational Site, Marilao, Bulacan

100029

GSK Investigational Site, Beijing

100034

GSK Investigational Site, Beijing

100050

GSK Investigational Site, Beijing

110015

GSK Investigational Site, Shenyang

200433

GSK Investigational Site, Shanghai

266071

GSK Investigational Site, Qingdao

310003

GSK Investigational Site, Hangzhou

310016

GSK Investigational Site, Hangzhou

400037

GSK Investigational Site, Chongqing

411706

GSK Investigational Site, Ilsanseo-gu, Goyang-si, Gyeonggi-do

518020

GSK Investigational Site, Shenzhen

524001

GSK Investigational Site, Zhanjiang

530021

GSK Investigational Site, Nanning

570311

GSK Investigational Site, Haikou

710032

GSK Investigational Site, Xi'an

750004

GSK Investigational Site, Yinchuan

Unknown

GSK Investigational Site, Chongqing

420-767

GSK Investigational Site, Bucheon-si, Gyeonggi-Do

361-711

GSK Investigational Site, Cheongju, Chungcheongbuk-do

602-739

GSK Investigational Site, Pusan